Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

NYSE:LUMN
NYSE:LUMNTelecom

The Bull Case For Lumen Technologies (LUMN) Could Change Following Leadership Reshuffle And New President Appointment

Earlier this month, Lumen Technologies announced that long-serving board leaders T. Michael Glenn and Hal Stanley Jones will retire after the 2026 Annual Meeting, while General Kevin P. Chilton is set to become Chair and long-time CFO Christopher D. Stansbury has been appointed President as of March 13, 2026. This reshaping of Lumen’s leadership team, separating the CEO and President roles and elevating a finance-focused executive, highlights a governance and operational shift that could...
NYSE:OC
NYSE:OCBuilding

Owens Corning (OC) Valuation Check After Recent Share Price Pullback

Owens Corning stock snapshot after recent performance Owens Corning (OC) has drawn fresh attention after a recent share price pullback, with the stock down about 14% over the past month and roughly 7% over the past 3 months. See our latest analysis for Owens Corning. That recent pullback sits within a weaker stretch for Owens Corning, with a 30 day share price return of a 14.3% decline and a 1 year total shareholder return of a 24.9% loss, suggesting momentum has faded after earlier multi...
NasdaqGS:TW
NasdaqGS:TWCapital Markets

A Look At Tradeweb Markets (TW) Valuation After Recent Share Price Pullback

Why Tradeweb Markets (TW) is on investors’ radar today Tradeweb Markets (TW) has drawn fresh attention after recent share price moves, with the stock down about 1% over the past day and roughly 7% over the past week. Against that shorter term weakness, the company shows a gain in the past 3 months and a positive year to date return. This has prompted some investors to revisit how its electronic marketplaces business and current valuation line up. See our latest analysis for Tradeweb...
NYSE:JCI
NYSE:JCIBuilding

Is It Too Late To Consider Johnson Controls (JCI) After Smart Building Project Momentum?

Curious whether Johnson Controls International at around US$131 per share still offers value, or if most of the opportunity is already reflected in the price. The stock has posted a 7.3% return year to date, with a 1.2% move over the last week, a 9.0% decline over the past month, and longer term returns of 67.0% over 1 year, 131.1% over 3 years, and 142.6% over 5 years. Recent headlines around large scale energy efficiency projects, smart building solutions, and broader attention on...
SEHK:9969
SEHK:9969Biotechs

A Look At InnoCare Pharma (SEHK:9969) Valuation After Recent Share Price Momentum

Recent share performance and business snapshot InnoCare Pharma (SEHK:9969) has drawn investor attention after a 5.7% one day gain, adding to a one month return of 12.8% and a past 3 months return recorded as 0%. The Hong Kong listed biopharmaceutical group focuses on cancer and autoimmune disease treatments in China, with revenue of CN¥2,374.906 million and net income of CN¥642.467 million reported in its latest figures. See our latest analysis for InnoCare Pharma. At the current share price...
NYSE:IIPR
NYSE:IIPRIndustrial REITs

A Look At Innovative Industrial Properties (IIPR) Valuation After The PharmaCann Settlement Resolves Rent Disputes

Why the PharmaCann settlement matters for IIPR Innovative Industrial Properties (IIPR) has drawn attention after reaching a settlement with PharmaCann to resolve rent default lawsuits, terminate three property leases, and regain possession of facilities in New York, Ohio, and Pennsylvania. See our latest analysis for Innovative Industrial Properties. The PharmaCann settlement lands at a time when momentum in IIPR’s share price is soft in the short term, with a 30 day share price return...
NasdaqCM:VKTX
NasdaqCM:VKTXBiotechs

The Bull Case For Viking Therapeutics (VKTX) Could Change Following Full VK2735 Phase 3 Enrollment Progress

Viking Therapeutics recently completed patient enrollment in its Phase 3 VANQUISH-2 trial of once-weekly subcutaneous VK2735 in roughly 1,000 adults with obesity and type 2 diabetes, a pivotal study running 78 weeks with weight loss as the primary endpoint. This milestone moves VK2735 further along a path already supported by earlier Phase 2 data showing meaningful weight reduction and an encouraging safety profile, directly linking Viking’s pipeline to the rapidly expanding GLP-1/GIP...
TSX:CG
TSX:CGMetals and Mining

Is It Too Late To Reassess Centerra Gold (TSX:CG) After Its 161% One Year Surge

If you are wondering whether Centerra Gold is still reasonably priced after a strong run, this breakdown will help you see how the current share price stacks up against its underlying value. The stock last closed at $23.23, with returns of 7.1% over 7 days, a 19.0% decline over 30 days, 19.6% year to date, 161.0% over 1 year, 191.1% over 3 years and 137.6% over 5 years. This naturally raises questions about how much optimism is already reflected in the price. Recent coverage has focused on...
SEHK:3393
SEHK:3393Electronic

Assessing Wasion Holdings (SEHK:3393) Valuation After Strong Earnings And Major Brazilian Contract Win

Earnings and Contract Win Set the Scene for Wasion Holdings Wasion Holdings (SEHK:3393) has drawn fresh attention after reporting full year 2025 earnings, alongside securing an exclusive recloser supply contract with Brazilian power group Companhia Energética de Minas Gerais S.A. See our latest analysis for Wasion Holdings. The recent earnings release and Brazilian contract news arrive after a strong run in the shares, with a 90 day share price return of 75.81% and a 1 year total shareholder...
XTRA:KTN
XTRA:KTNIT

Kontron (XTRA:KTN) Valuation After Full Year Earnings Reveal Lower Sales But Stronger Profitability

Kontron (XTRA:KTN) shares are in focus after the company reported full year 2025 results, with sales of €1,652.4 million along with higher net income and earnings per share compared to the previous year. See our latest analysis for Kontron. The earnings announcement appears to have triggered a sharp 1 day share price return of 6.67%, although this comes after a weaker patch, with 30 day and year to date share price returns of 18.91% and 17.29% declines respectively. The 3 year total...
NasdaqGS:PLAB
NasdaqGS:PLABSemiconductor

Assessing Photronics (PLAB) Valuation After Sector Jitters From Google TurboQuant Announcement

Google’s TurboQuant algorithm announcement, which aims to cut AI memory needs, shook semiconductor sentiment. Photronics (PLAB) dropped 6.8% as investors quickly reassessed demand expectations for memory related manufacturing businesses. See our latest analysis for Photronics. That sharp 6.8% drop comes after a stronger run, with the share price showing a 20.11% 90 day return and an 18.53% year to date return, while the 1 year total shareholder return of 92.23% highlights how much sentiment...
NYSE:WOR
NYSE:WORMachinery

A Look At Worthington Enterprises (WOR) Valuation After Strong Q3 Growth And Data Center Demand

Worthington Enterprises (WOR) has put fresh numbers on the table, with third quarter fiscal 2026 results showing higher sales, earnings and earnings per share, supported by acquisitions and data center related demand. See our latest analysis for Worthington Enterprises. The latest earnings update, buyback progress and ongoing dividends come against a mixed share price backdrop, with a 7 day share price return of 6.42% contrasting with a 30 day share price decline of 9.48%, while the 3 year...
NYSE:GEL
NYSE:GELOil and Gas

Assessing Genesis Energy (GEL) Valuation As Sexual Assault Lawsuit Raises Governance Concerns

Genesis Energy (GEL) is facing a sexual assault lawsuit in Harris County State Court that names the company and a current board member, with Jane Doe seeking US$50 million in compensatory and punitive damages. See our latest analysis for Genesis Energy. The lawsuit lands at a time when Genesis Energy’s share price, now at US$17.78, has pulled back 2.79% over one day but still carries an 11.96% year to date share price return and an 18.10% one year total shareholder return. This builds on a...
NasdaqCM:MBIN
NasdaqCM:MBINDiversified Financial

Assessing Merchants Bancorp (MBIN) Valuation After Recent Mixed Share Price Performance

Recent Performance Snapshot Merchants Bancorp (MBIN) has drawn fresh attention after a mixed short term return pattern, with a 2.2% decline over the past day, a 2.6% gain over the past week, and a flat month. See our latest analysis for Merchants Bancorp. Looking beyond the latest moves, the 90 day share price return of 26.44% sits alongside a 1 year total shareholder return of 15.44%. This suggests recent momentum has been stronger than the longer term outcome. If you are comparing Merchants...
NYSE:BLK
NYSE:BLKCapital Markets

Is BlackRock (BLK) Offering Opportunity After Recent Share Price Pullback

If you are wondering whether BlackRock's current share price reflects its true value, you are not alone. This article focuses exactly on that question. The stock last closed at US$933.85, with returns of 0.7% over 1 year, 49.8% over 3 years, and 37.2% over 5 years, while the year to date return sits at a 13.9% decline and the past month shows a 12.2% decline. Recent coverage has centered on BlackRock's role as a major global asset manager, its influence across exchange traded funds, and its...
NYSE:FLS
NYSE:FLSMachinery

Is Flowserve (FLS) Still Attractive After Its Recent 18.5% One Month Share Price Decline

If you are wondering whether Flowserve's current share price still offers value, it helps to look past the headline moves and focus on what the underlying numbers are saying about the stock. The share price recently closed at US$72.15, with returns of 1.1% over 7 days, a 18.5% decline over 30 days, 2.0% year to date, 50.0% over 1 year, 123.1% over 3 years, and 102.4% over 5 years. This gives a mixed picture of shorter term swings versus longer term performance. Recent coverage around...
NYSE:G
NYSE:GProfessional Services

Evaluating Genpact (G) After Recent Share Price Weakness And A Claimed 25% Valuation Discount

Genpact stock moves: recent performance snapshot Genpact (G) has drawn investor attention after a period of weaker share performance, with the stock showing a 2.2% decline over the past day and deeper losses over the past month and past 3 months. See our latest analysis for Genpact. At a share price of US$36.58, Genpact’s recent 7 day and 30 day share price returns of 5.48% and 7.91% declines, alongside a 1 year total shareholder return of 25.62% decline, suggest momentum has been fading as...
NYSE:FRT
NYSE:FRTRetail REITs

Federal Realty Expands Rockville Pike Cluster With Congressional North Purchase

Federal Realty Investment Trust (NYSE:FRT) has acquired the Congressional North Shopping Center in Montgomery County, Maryland. The property is located along Rockville Pike in the Washington DC Metro area, a densely populated and affluent retail corridor. The deal expands Federal Realty's ownership cluster in one of the country's most established retail corridors. Federal Realty Investment Trust, a retail focused REIT, is known for owning and operating open air shopping centers and mixed...
NYSE:AMPX
NYSE:AMPXElectrical

Is It Too Late To Consider Buying Amprius Technologies (AMPX) After Its Recent Surge In Price?

If you are asking whether Amprius Technologies at US$16.12 is still attractively priced or already running ahead of itself, the next sections walk through the key numbers you need to weigh that up. The stock has been volatile recently, with an 11.4% decline over the past 7 days, a 50.2% gain over 30 days, an 84.4% return year to date and a very large 1 year return of 473.7%. Recent coverage has focused on Amprius as a high growth, high volatility name in the Electrical industry, and those...
SEHK:883
SEHK:883Oil and Gas

Is It Too Late To Consider CNOOC (SEHK:883) After A 69% One-Year Surge?

Wondering whether CNOOC’s current share price still offers value after a strong run, or if you may be turning up late to the story. CNOOC shares last closed at HK$29.06, with returns of 17.8% over 30 days, 32.9% year to date, and 69.2% over 1 year, while the 7 day return shows a 4.3% pullback that may have changed how investors view the near term risk and reward. Recent news flow around CNOOC has focused on its role in global energy markets and investor attention on large oil and gas...
NasdaqGM:LGND
NasdaqGM:LGNDPharmaceuticals

Does Ligand’s Royalty-Focused Leadership Shuffle Reveal a New Strategic Inflection Point for LGND?

In March 2026, Ligand Pharmaceuticals expanded its leadership team by appointing healthcare investors Peter Renehan, MD, and Lee Brown as Vice Presidents of Investments and Business Development, while broadening Lauren Hay’s role to Vice President of Portfolio Strategy and Investments to focus on royalty financing and portfolio optimization. Around the same time, Chief Financial Officer Octavio Espinoza sold 3,057 shares for about US$688,000 under a prearranged 10b5-1 plan, alongside company...
NasdaqGS:IMKT.A
NasdaqGS:IMKT.AConsumer Retailing

Is Ingles Markets (IMKT.A) Proxy Fight Reframing Its Governance And Executive Pay Investment Story?

In March 2026, Ingles Markets and activist investor Summer Road LLC entered a heated proxy fight, filing competing proxy statements over board seats and a non-binding executive pay proposal ahead of the April 30, 2026 annual meeting. This contest highlights growing shareholder pressure on Ingles Markets’ governance and executive compensation practices, putting board composition and accountability under closer scrutiny. Next, we will examine how this proxy contest over board representation...
NasdaqGM:MDB
NasdaqGM:MDBIT

Assessing MongoDB (MDB) Valuation After Recent Share Weakness And Conflicting Fair Value Estimates

Recent share performance and business context MongoDB (MDB) has drawn investor attention after a period of weaker share performance, with the stock showing negative returns over the past week, month and past 3 months, alongside a negative year to date move. This share price backdrop sits against annual revenue of US$2.46b and a reported net loss of US$71.15m, raising questions about how investors should weigh growth in its database platform against profitability and valuation today. See our...
NasdaqGS:REGN
NasdaqGS:REGNBiotechs

Assessing Regeneron Pharmaceuticals (REGN) Valuation After Japan’s New Dupixent Approval

Regeneron Pharmaceuticals (REGN) is back in focus after Japan’s Ministry of Health, Labour and Welfare approved Dupixent for adults with moderate to severe bullous pemphigoid, expanding the drug’s footprint in a rare inflammatory skin disease. See our latest analysis for Regeneron Pharmaceuticals. Even with the positive Dupixent news, Regeneron’s short term share price return has been muted. The 7 day share price return is 0.66% and the 30 day share price return reflects a 5.62% decline. The...